GlobeNewsWire
24 Mar 2026, 22:00 UTC · 26w ago
Verdict
Headline takes no side. We score CORT −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) refusing approval for Corcept's relacorilant for the treatment of hypercortisolism due to insufficient evidence of effectiveness.
So whatThe denial of a primary drug candidate's approval is a major fundamental blow to a biotech company's valuation and revenue pipeline.
More negative than 99% of claims this week
Corcept is facing a securities fraud class action lawsuit alleging it misled investors regarding the FDA's concerns and the likelihood of relacorilant's approval.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 86% of claims this week
The FDA had warned Corcept on several occasions during pre-submission meetings to expect significant review issues with the relacorilant clinical development program.
More negative than 78% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud class action lawsuit following an FDA rejection of its drug relacorilant and significant stock price drops.
More negative than 77% of ticker scores this week
The company is the subject of an ongoing investigation by a plaintiffs' law firm.
More negative than 77% of ticker scores this week
The company is being mentioned in the context of a legal investigation by a plaintiffs' law firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
3h ago
+247.4%
Price is moving against the score
$117.50 vs $33.82 close before publication (Mar 24) · not market-adjusted
CORT chart →